Oxaquin (prodrug of MCB3681)

Synonym(s): DNV3837  |  MCB3837

Class: Fluoroquinolone-oxazolidinone hybrid

Spectrum of activity:	Gram-negative
Details of activity:	C. difficile infections
Description:	Gray CP, Cappi MW, Frimodt-Moller N. Efficacy studies of MCB 3837, a dual-action antibiotic, in experimental infections in mice. 45th-Intersci-Conf-Antimicrob-Agents-Chemother 2005;185
Institute where first reported:	Morphochem AG (Biovertis, Vienna); Evotec AG, Germany
Year first mentioned:	2005
Highest developmental phase:	Phase 1
Development status:	Unknown
Reason Dropped:	Evotec and Bioveris collaborated to take this into phase II trials but there has been nothing to suggest it was taken into phase II. It was in phase I trials for nosocomial infections and CAP (source)

Chemical structure(s):
Canonical SMILES:	CC(=O)NC[C@H]1CN(C2=CC=C(C(=C2)F)OCC3(CCN(CC3)C4=CC5=C(C=C4F)C(=O)C(=CN5C6CC6)C(=O)O)OP(=O)(O)[O-])C(=O)O1.[Na+]
Isomeric SMILES:	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)OCC3(CCN(CC3)C4=C(C=C5C(=C4)N(C=C(C5=O)C(=O)O)C6CC6)F)OP(=O)(O)[O-])F.[Na+]
InChI:	InChI=1S/C31H33F2N4O11P.Na/c1-17(38)34-13-20-14-37(30(42)47-20)19-4-5-27(24(33)10-19)46-16-31(48-49(43,44)45)6-8-35(9-7-31)26-12-25-21(11-23(26)32)28(39)22(29(40)41)15-36(25)18-2-3-18;/h4-5,10-12,15,18,20H,2-3,6-9,13-14,16H2,1H3,(H,34,38)(H,40,41)(H2,43,44,45);/q;+1/p-1/t20-;/m0./s1
InChI Key:	YJXYMDNRYHCPHB-BDQAORGHSA-M
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/44201349

External links:
Guide to Pharmacology:	oxaquin
Main Source:	https://www.businesswire.com/news/home/20180412006425/en/DEINOVE-Takes-New-Dimension-Acquisition-MORPHOCHEM%E2%80%99s-Clinical-Stage
Citation:	https://www.globenewswire.com/news-release/2019/05/16/1826433/0/en/DEINOVE-is-now-ready-to-start-Phase-II-clinical-trial-for-its-antibiotic-compound-DNV3837.html